Zacks Research Weighs in on STERIS plc’s Q2 2025 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Research analysts at Zacks Research cut their Q2 2025 EPS estimates for shares of STERIS in a note issued to investors on Tuesday, August 27th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.17 per share for the quarter, down from their previous forecast of $2.22. The consensus estimate for STERIS’s current full-year earnings is $9.17 per share. Zacks Research also issued estimates for STERIS’s Q3 2025 earnings at $2.34 EPS, Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.14 EPS, Q2 2026 earnings at $2.30 EPS, Q4 2026 earnings at $2.83 EPS and FY2026 earnings at $10.04 EPS.

Several other research firms have also recently commented on STE. Piper Sandler reaffirmed a “neutral” rating and issued a $225.00 target price (up from $220.00) on shares of STERIS in a research report on Friday, May 10th. StockNews.com raised shares of STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. JMP Securities reissued a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research report on Wednesday, August 7th. Stephens reissued an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Wednesday, August 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $243.60.

STERIS Trading Up 1.4 %

NYSE:STE opened at $241.10 on Thursday. The company has a 50-day moving average price of $228.94 and a 200-day moving average price of $224.50. STERIS has a 12 month low of $195.47 and a 12 month high of $243.37. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. The stock has a market cap of $23.78 billion, a price-to-earnings ratio of 63.12 and a beta of 0.83.

STERIS (NYSE:STE) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $1.98 by $0.16. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The firm had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period last year, the company posted $2.00 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, September 5th will be given a dividend of $0.57 per share. This is a boost from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date is Thursday, September 5th. STERIS’s dividend payout ratio (DPR) is 54.45%.

Insider Activity at STERIS

In other STERIS news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.14% of the stock is currently owned by corporate insiders.

Institutional Trading of STERIS

Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in shares of STERIS by 8.3% in the first quarter. Russell Investments Group Ltd. now owns 58,841 shares of the medical equipment provider’s stock worth $13,235,000 after acquiring an additional 4,494 shares during the period. State Board of Administration of Florida Retirement System grew its stake in shares of STERIS by 3.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 106,346 shares of the medical equipment provider’s stock worth $23,909,000 after acquiring an additional 3,342 shares during the period. Caden Capital Partners LP grew its stake in shares of STERIS by 80.0% in the fourth quarter. Caden Capital Partners LP now owns 82,312 shares of the medical equipment provider’s stock worth $18,096,000 after acquiring an additional 36,576 shares during the period. Diversify Advisory Services LLC bought a new stake in shares of STERIS in the first quarter worth approximately $903,000. Finally, Perpetual Ltd grew its stake in shares of STERIS by 9.3% in the first quarter. Perpetual Ltd now owns 40,571 shares of the medical equipment provider’s stock worth $9,121,000 after acquiring an additional 3,437 shares during the period. 94.69% of the stock is currently owned by institutional investors.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.